An observational study in Pregnancy Related, sponsored by Sun Pharmaceutical Industries Limited. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Sun Pharmaceutical Industries Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to tildrakizumab during pregnancy to treat an approved indication.
The pregnancy registry cohort study will be conducted by the Organization of Teratology Information Specialists (OTIS), which is a network of university and health department based information centers serving pregnant women and healthcare providers throughout North America. These services provide a basis for collaborative research such as this Registry.
These Services located throughout the United States (US) and Canada will serve as a source of referrals not only for tildrakizumab-exposed pregnancies but also for similarly ascertained disease-matched comparison pregnant women who have not used tildrakizumab in pregnancy.
The target follow-up period will be until end of pregnancy and 1 year of age for live born infants.
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pregnant women diagnosed with tildrakizumab-approved indication with and without tildrakizumab
Cohort 1: Tildrakizumab-Exposed Cohort
Cohort 2: Disease-Matched Comparison Cohort
Exclusion criteria:
Cohort 1: Tildrakizumab-Exposed Cohort:
Cohort 2: Disease-Matched Comparison Cohort
Exposure to tildrakizumab for the treatment of an approved indication
Drug: Pregnant women exposed to tildrakizumab
No exposure to tildrakizumab at any time in the current pregnancy
Drug: Pregnant women not exposed to tildrakizumab
Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
Major structural defects in children
defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects
Time frame: Up to 1 year of age
Spontaneous abortion/miscarriage
defined as non-deliberate fetal death that occurs prior to 20.0 weeks post-last menstrual period
Time frame: 20 weeks post-last menstrual period
Stillbirth
defined as non-deliberate fetal death anytime in gestation at or after 20.0 weeks post-last menstrual period
Time frame: from 20 weeks post-last menstrual period to end of pregnancy
Elective termination/abortion
defined as deliberate discontinuation of pregnancy through medication or surgical procedures
Time frame: At the end of pregnancy or through 9 month pregnancy period
neonatal/infant death
defined as any death in a live born infant during the first 6 months of age
Time frame: 6 months of age
Small for gestational age
defined as birth size (weight, length, or head circumference) less than or equal to the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants
Time frame: at birth
Postnatal growth deficiency
defined as postnatal size (weight, length or head circumference) less than or equal to the 10th centile for sex and age using standard pediatric growth curves and adjusted for postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age
Time frame: Up to 1 year of age
Malignancies in live born children
defined as any malignancy reported in an infant within the first year of life
Time frame: Up to 1 year of age
Hospitalization in live born children
defined as any hospitalization of the infant within the first year of life after discharge following delivery
Time frame: Up to 1 year of age
Postnatal serious or opportunistic infection in live born children
defined as any infection resulting in hospitalization, X-ray proven pneumonia, neonatal sepsis, meningitis, osteomyelitis, bacteremia, septic arthritis, abscess, mycobacteria infections, invasive fungal infection including histoplasmosis, coccidiomycosis, candidiasis, aspergillosis, and blastomycosis, pneumocystis jirovecii infection, systemic cytomegalovirus, herpes zoster and herpes simplex infection, listeria infections, and Legionella infection.
Time frame: Up to 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2019 (actual). Primary completion is estimated for Jul 2028, 107 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Pharmaceutical Industries Limited →